These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9081204)

  • 1. Immunoregulatory mechanisms in multiple myeloma.
    Munshi NC
    Hematol Oncol Clin North Am; 1997 Feb; 11(1):51-69. PubMed ID: 9081204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoregulatory circuits in myeloma. Tumor cell cytotoxicity mediated by soluble CD16.
    Hoover RG; Lary C; Page R; Travis P; Owens R; Flick J; Kornbluth J; Barlogie B
    J Clin Invest; 1995 Jan; 95(1):241-7. PubMed ID: 7529259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
    Miura T; Ghanta VK; Hiramoto RN
    Cancer Invest; 1990; 8(1):17-25. PubMed ID: 2350718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoregulation of murine and human myeloma.
    Hoover RG; Kornbluth J
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):407-24. PubMed ID: 1582982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormalities in immunoregulatory CD5+ B cells precede the diagnosis of multiple myeloma.
    Paglieroni T; MacKenzie MR; Caggiano V
    Ann N Y Acad Sci; 1992 May; 651():486-7. PubMed ID: 1376067
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.
    Murillo O; Arina A; Hervas-Stubbs S; Gupta A; McCluskey B; Dubrot J; Palazón A; Azpilikueta A; Ochoa MC; Alfaro C; Solano S; Pérez-Gracia JL; Oyajobi BO; Melero I
    Clin Cancer Res; 2008 Nov; 14(21):6895-906. PubMed ID: 18980984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma.
    Pilarski LM; Masellis-Smith A; Szczepek A; Mant MJ; Belch AR
    Leuk Lymphoma; 1996 Aug; 22(5-6):375-83. PubMed ID: 8882950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of surface immunoglobulin in murine and human myeloma and chronic lymphocytic leukemia.
    Heller P
    Ann Clin Lab Sci; 1978; 8(3):254-7. PubMed ID: 306797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific detection of myeloma plasma cells using anti-idiotypic single chain antibody fragments selected from a phage display library.
    Willems PM; Hoet RM; Huys EL; Raats JM; Mensink EJ; Raymakers RA
    Leukemia; 1998 Aug; 12(8):1295-302. PubMed ID: 9697887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.
    Lozano E; Díaz T; Mena MP; Suñe G; Calvo X; Calderón M; Pérez-Amill L; Rodríguez V; Pérez-Galán P; Roué G; Cibeira MT; Rosiñol L; Isola I; Rodríguez-Lobato LG; Martin-Antonio B; Bladé J; Fernández de Larrea C
    J Immunol; 2018 Apr; 200(8):2581-2591. PubMed ID: 29531171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-bound immunoglobulin on peripheral blood mononuclear cells of patients with myeloma.
    King MA; Wells JV
    Clin Exp Immunol; 1981 Sep; 45(3):552-6. PubMed ID: 6175455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoregulatory T cell function in multiple myeloma.
    Ozer H; Han T; Henderson ES; Nussbaum A; Sheedy D
    J Clin Invest; 1981 Mar; 67(3):779-89. PubMed ID: 6451635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoregulatory circuits in myeloma.
    Ullrich S; Zolla-Pazner S
    Clin Haematol; 1982 Feb; 11(1):87-111. PubMed ID: 7042151
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression.
    Wearne AJ; Joshua DE; Brown RD; Kronenberg H
    Br J Haematol; 1987 Sep; 67(1):39-44. PubMed ID: 2959309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The increase of CD5LOW+NK cells in patients with multiple myeloma and plasmacytoma.
    Ishiyama T; Watanabe K; Fukuchi K; Yajima K; Koike M; Tomoyasu S; Tsuruoka N
    Anticancer Res; 1994; 14(2B):725-30. PubMed ID: 7516640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypogammaglobulinemia in experimental myeloma: the role of suppressor factors from mononuclear phagocytes.
    Krakauer RS; Strober W; Waldmann TA
    J Immunol; 1977 Apr; 118(4):1385-90. PubMed ID: 850068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of FcR+ T cells and of IgG-BF in the control of myeloma cells.
    Teillaud JL; Brunati S; Elmalek M; Astier A; Nicaise P; Moncuit J; Mathiot C; Job-Deslandre C; Fridman WH
    Mol Immunol; 1990 Dec; 27(12):1209-17. PubMed ID: 2148806
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma.
    Seegmiller AC; Xu Y; McKenna RW; Karandikar NJ
    Am J Clin Pathol; 2007 Feb; 127(2):176-81. PubMed ID: 17210522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM).
    Kyrtsonis MC; Mouzaki A; Maniatis A
    Med Oncol; 1999 Jul; 16(2):73-7. PubMed ID: 10456654
    [No Abstract]   [Full Text] [Related]  

  • 20. [Idiotypic study of human myeloma].
    Boccadoro M; Gavarotti P; Massaia M; Pileri A
    Minerva Med; 1982 Apr; 73(18):1175-8. PubMed ID: 6979012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.